A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. (GLOFTST)

Soochow University

Status: Enrolling

Conditions: B-cell Non-Hodgkin Lymphoma

Treatments: Drug: Glofitamab

Study type: Observational

Funder types: Other

Identifiers

NCT06497452

GLOFTST

Details and patient eligibility

About

The purpose of this study is to assess the efficacy and safety in the real-world settings of glofitamab in combination with salvage therapy among Chinese adult patients with relapsed or refractory B-cell non-hodgkin lymphoma.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Be diagnosed as B-NHL
• Relapse or refractory to previous treatment
• Participants who will be treated with glofitamab

Exclusion criteria

• Participant who currently participates in or with plan to participate in any interventional clinical trial
• Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.

Trial design

50 participants in 1 patient group

Observational Cohort

Treatment:

Drug: Glofitamab